Case | Age | Gender | Clinical Presentation | Site | Size (Maximum Diameter) | Mitosis (50/HPF) | NIH Risk Classification | AJCC stage | Cell type (histologic subtype) | Treatment | Follow-up Information |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 63 | M | hematochezia | rectum | 6 cm | 5 | High | II | Mixed(hypercellular spindle + hypercellular epithelioid) | excision and imatinib(400 mg) | NED at 61 mo |
2 | 69 | M | asymptomatic | ileum | 5.5 cm | 4 | High | II | Mixed(sclerosing spindle + sclerosing epithelioid ) | excision and imatinib(400 mg) | NED at 45 mo |
3 | 63 | F | asymptomatic | stomach | 5.2 cm | 2 | Moderate | IB | Mixed(sclerosing spindle + sclerosing and dyscohesive epithelioid) | excision and imatinib(200 mg) | NED at 43 mo |
4 | 83 | M | abdominal mass | jejunum | 21.3 cm | 10 | High | IIIB | Mixed(hypercellular spindle + hypercellular epithelioid ) | excision and imatinib(400 mg) | NED at 39 mo |
5 | 62 | M | abdominal pain | duodenum | 7 cm | 8 | High | IIIB | Mixed(sclerosing spindle + dyscohesive and sclerosing epithelioid) | excision and imatinib(400 mg) | NED at 22 mo |
6 | 70 | M | asymptomatic | stomach | 6 cm | 2 | Moderate | IB | Mixed(sclerosing spindle + dyscohesive epithelioid) | excision | NED at 21 mo |
7 | 57 | F | abdominal pain | jejunum | 5.4 cm | 2 | High | II | Mixed(sclerosing spindle + sclerosing and dyscohesive epithelioid) | excision | NED at 12 mo |
8 | 64 | M | abdominal mass | retroperitoneum | 10.5 cm | 2 | High | IIIA | Mixed(hypercellular and palisade-vacuolated spindle + epithelioid) | excision and imatinib(600 mg) | NED at 10 mo |